Background: Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA) measurement.Case presentation: We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index) to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan®, 11C-5HTP-PET/CT and 68Ga-DOTA-PET/CT in a patient with NET.Conclusions: Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests this parameter may also have utility as an index of therapeutic efficacy.
CITATION STYLE
Modlin, I. M., Drozdov, I., Bodei, L., & Kidd, M. (2014). Blood transcript analysis and metastatic recurrent small bowel carcinoid management. BMC Cancer, 14(1). https://doi.org/10.1186/1471-2407-14-564
Mendeley helps you to discover research relevant for your work.